- |||||||||| Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
Psoriatic onycho-pachydermo periostitis (POPP): a case report (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 1)) - Feb 20, 2024 - Abstract #AAD2024AAD_2950;
Treatment typically presents challenges, but there have been recent reports of promising clinical responses to anti-TNF-? therapies, and more recently, secukinumab.
- |||||||||| Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO) (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 1)) - Feb 20, 2024 - Abstract #AAD2024AAD_2944;
The adjusted ORs (95% CIs) of achieving PASI100 (M12) for the IL-17A/RA cohort, was 1.3 (1.02,1.71), 2.0 (1.24,2.61) and 0.9 (0.77,1.14) compared to TNF-?, IL-12/23 p40, and IL-23 p19 cohorts respectively. This analysis highlighted the short- and long-term effectiveness and durability of anti-IL-17A/RA biologics compared to other biologic classes.
- |||||||||| A Secret Shopper Assesssment of Psoriasis Drug Manufacturer Assistance Programs Reveals Widely Variable Enrollment Rates and Communication Challenges Across Enrollment Plans (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 2)) - Feb 20, 2024 - Abstract #AAD2024AAD_2899;
Applications were submitted for PDMAPs associated with risankizumab-rzaa, adalimumab, ixekizumab, guselkumab, secukinumab, apremilast, tildrakizumab-asmn, and brodalumab. There are significant timeliness and enrollment differences across PDMAPs.
- |||||||||| Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp, Humira (adalimumab) / AbbVie
Outcome of psoriasis patients switched from adalimumab originator to biosimilar: a retrospective, observational study () - Feb 20, 2024 - Abstract #AAD2024AAD_2896;
Background As a cost saving measure, psoriasis patients established on adalimumab originator (Humira) were switched to adalimumab biosimilar, Imraldi...31 patients were switched back to originator/alternative biosimilar (Amgevita)...Patients who successfully switched back to the originator, did not re-achieve the same disease control as before switching. Factors associated with switching failure included: male sex, higher weight, high-impact sites involvement and presence of concomitant PsA.
- |||||||||| Response to therapy in skin of colour participants with moderate-to-severe psoriasis and atopic dermatitis: a systematic review () - Feb 20, 2024 - Abstract #AAD2024AAD_2895;
However, differences in baseline characteristics[5] or comorbidities[6] were found, suggesting race or ethnic background should be considered when treatment is prescribed in psoriasis or atopic dermatitis. Although no significant SOC participant differential response to treatment were found, large-scale phase 3 trials investigating comparable treatment outcomes and stratifying results by SOC population in moderate-to-severe atopic dermatitis and psoriasis are needed to confirm these findings.
- |||||||||| Humira (adalimumab) / AbbVie
Intraleukin 17, hidradenitis suppurativa and response to adalimumab therapy (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 1)) - Feb 20, 2024 - Abstract #AAD2024AAD_2536;
Therefore, drugs targeting IL17 and being tested in clinical trials with promising results. Studying the predominant immune pathway in subjects with moderate to severe HS may help select the most appropriate treatment for each case, although more studies are needed to achieve standardization.
- |||||||||| Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie, Rituxan (rituximab) / Roche
Patient Demographics and Treatment Strategies Observed in The Follicular Occlusion Triad and Tetrad () - Feb 20, 2024 - Abstract #AAD2024AAD_2368;
Although the FOT is commonly described among dermatology literature, this review highlights the lack of an established FOT treatment algorithm. Future experimental studies are needed to compare the efficacy of the treatment options discussed in this review.
- |||||||||| Humira (adalimumab) / AbbVie
Treatment Adherence in Hidradenitis Suppurativa: A Systematic Review () - Feb 20, 2024 - Abstract #AAD2024AAD_2337;
Rates of discontinuation of second-line therapies are high, emphasizing the urgent need to develop effective treatments for refractory HS. This systematic review highlights the barriers to treatment adherence in HS patients and underscores the need to consider the patient
- |||||||||| Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Predictors of drug survival in patients with hidradenitis suppurativa treated with TNF-alpha-inhibitors (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 1)) - Feb 20, 2024 - Abstract #AAD2024AAD_2333;
Patients with younger age, obesity, Hurley Stage III disease, and groin involvement were more likely to fail adalimumab. No statistically significant predictors of infliximab response were identified, despite this being the largest reported cohort to date, suggesting a need for more nuanced data (e.g., biomarkers or genetic data) and/or larger sample size.
- |||||||||| Humira (adalimumab) / AbbVie
Efficacy of 80 mg/week dose of adalimumab (Humira) in treatment of hidradenitis suppurativa () - Feb 20, 2024 - Abstract #AAD2024AAD_2302;
We present a series of fifteen such patients whose response to an 80 mg/week dose of adalimumab has been positive, with a decrease in severity and number of HS lesions, leading to improvement in the Hidradenitis Suppurativa Clinical Response (HiSCR) in the absence of serious adverse effects. Although this dosing regimen has not been well-documented in literature, it is important to consider the lasting benefits of treatment with a higher dose in individuals afflicted with treatment-resistant HS, including a decreased likelihood of comorbidities and complications and an improved quality of life.
- |||||||||| Humira (adalimumab) / AbbVie
Use of an Estimated Hurley (eHurley) Score to Assess the Patient Journey in Hidradenitis Suppurativa () - Feb 20, 2024 - Abstract #AAD2024AAD_2270;
Although this dosing regimen has not been well-documented in literature, it is important to consider the lasting benefits of treatment with a higher dose in individuals afflicted with treatment-resistant HS, including a decreased likelihood of comorbidities and complications and an improved quality of life. The use of estimated Hurley scores allows better tracking of HS disease severity in the assessment of real-world management.
- |||||||||| Humira (adalimumab) / AbbVie
Adalimumab dose escalation in patients with refractory hidradenitis suppurativa (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 1)) - Feb 20, 2024 - Abstract #AAD2024AAD_2266;
We found double-dose adalimumab produced significant improvement in both HS-PGA and NRS-pain for a cohort of predominantly obese patients with intractable HS receiving single dose therapy. Notwithstanding the study limitation of small sample size, further investigation of increased adalimumab dosage and its relation to BMI is warranted.
- |||||||||| Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp, Humira (adalimumab) / AbbVie
Interchangeability of SB5 and Adalimumab Reference Product in Patients with Moderate to Severe Chronic Plaque Psoriasis () - Feb 20, 2024 - Abstract #AAD2024AAD_2240;
Notwithstanding the study limitation of small sample size, further investigation of increased adalimumab dosage and its relation to BMI is warranted. Multiple switches between SB5 and RP have equivalent PK, with comparable efficacy, safety, and immunogenicity to continuation of RP.
- |||||||||| Remicade (infliximab) / J&J, Humira (adalimumab) / AbbVie
Impact of TNF-a Inhibitors on Emergency Department Visits in Hidradenitis Suppurativa Patients: A Retrospective Cohort Study (San Diego Convention Center (Upper Level, Sails Pavilion, Poster Center 1)) - Feb 20, 2024 - Abstract #AAD2024AAD_2209;
inhibitors in HS treatment and also implies a reduction in disease burden and perhaps improvement in QOL. The decreased reliance on high-cost services like the ED, where procedures such as I&D occur, suggests treatment with biologics could reduce financial burden for the patient and the healthcare system.
- |||||||||| Network Propagation Analysis to Elucidate the Molecular Mechanisms Underlying Drug-induced Pulmonary Arterial Hypertension (San Diego Convention Center, Room 28C-E (Upper Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_8218;
Implementing a pairwise approach, we first identified the colocalized subnetworks between PAH and known causal (dasatinib, ponatinib, and ruxolitinib) and mitigating (etanercept and adalimumab) drugs using curated gene sets for PAH and drugs. In summary, our network propagation-based analysis identified shared risk genes and pathways underlying drug-induced PAH, shedding light on the etiology of drug-induced PAH and potential drug repurposing strategies to mitigate adverse effects.
- |||||||||| Mycamine (micafungin) / Astellas, Humira (adalimumab) / AbbVie
A Rare Case of Necrotizing Pneumonia in an Immunocompromised Patient (San Diego Convention Center, Area I (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_2012;
While this patient's progressive hypoxic respiratory failure was multifactorial including from S. pneumoniae and COVID-19 pneumonia, his rapidly progressive necrotizing pneumonia was likely secondary to L. micdadei. Early diagnosis and treatment of L. micdadei is challenging yet essential, particularly in immunosuppressed patients, as this bacterium has statistically higher mortality rates than other causes of nosocomial pneumonia.
- |||||||||| Humira (adalimumab) / AbbVie
An Unusual Association of Diffuse Alveolar Hemorrhage in a Pediatric Patient (San Diego Convention Center, Area J (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_1848;
DAH can be a life-threatening complication associated with autoinflammatory disease. To our knowledge, this is the first reported case of DAH in a pediatric patient with BD.
- |||||||||| hydralazine hydrochloride / Generic mfg.
A Rare Case of Hydralazine-Induced Diffuse Alveolar Hemorrhage (San Diego Convention Center, Area A (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_1593;
Hydralazine is a widely used antihypertensive that can cause rare adverse effects like AAV and DAH, particularly with doses higher than 100mg/day. DAH can be rapidly progressive and fatal; hence, a thorough clinical and medication history, along with serology and pathology, are vital in making a diagnosis.
- |||||||||| Humira (adalimumab) / AbbVie
Adalimumab-Induced Desquamative Interstitial Pneumonia in a Nonsmoker (San Diego Convention Center, Area A (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_1592;
Drug induced ILD has poor prognosis with mortality up to 67% in patients with preexisting lung disease. Hence early recognition, cessation of offending agent, and treatment with immunosuppressants is of paramount importance.
- |||||||||| Humira (adalimumab) / AbbVie
Shrinking Lung Syndrome With Diaphragm Myopathy and Phrenic Neuropathy (San Diego Convention Center, Area A (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_1552;
He was treated with various lines of immunosuppression over the course of 18 months including moderate to high doses of Prednisone, Methotrexate, Mycophenolate, Adalimumab, Belilumab and Hydroxychloroquine without improvement in respiratory symptoms, imaging or spirometry...He is currently being trialed on cyclophosphamide with mild improvement in pleuritic chest pain after 2 doses...Phrenic neuropathy and diaphragm myopathy is not well described in the literature and likely under-recognized in this rare syndrome. The use of diaphragm EMG and phrenic NCS in patients with suspected SLS may better define subtypes of SLS, monitor patients for development of hypercapnic respiratory failure, and direct treatment to the underlying pathology.
- |||||||||| Humira (adalimumab) / AbbVie, Cosentyx (secukinumab) / Novartis
Progressive Interstitial Lung Disease Associated With Anti-MDA5 Positive Dermatomyositis (San Diego Convention Center, Area A (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_1546;
Recent publications have suggested a central role for INF-I mediated vasculopathy likely contributing to the cutaneous and lung manifestations. More research studies are needed to better understand this disease process and identify interventions.
- |||||||||| Humira (adalimumab) / AbbVie
Mass-Like Lesions on Chest CT in a Woman with Quiescent Crohn's Disease (San Diego Convention Center, Area A (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_1532;
The patient had not had a Crohn's flare for 9 years and discontinued adalimumab 4 months ago...The patient was discharged with a 7-day course of PO clindamycin and trimethoprim-sulfamethoxazole with a presumptive diagnosis of atypical pneumonia...The patient was treated with prednisone, and the pleurisy and lung lesions rapidly resolved...The patient had been off the TNFa inhibitor when she developed COP, which is also relevant, since TNFa inhibitors have been reported to cause secondary COP during treatment in various autoimmune diseases. Thus, it is crucial to consider COP in patients with autoimmune diseases, regardless of disease activity.
- |||||||||| Humira (adalimumab) / AbbVie
A Case of Adalimumab-induced Pleuritis (San Diego Convention Center, Area C (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_1509;
The patient was admitted and started on celecoxib, and adalimumab was discontinued by the rheumatology team...Rheumatology then diagnosed the patient with seronegative rheumatoid arthritis (RA), decided to switch the patient to methotrexate, and recommended against re-challenge with a TNF-alpha inhibitor in the future...The high eosinophil count encountered in this case would not be expected from RA, and the fact that the effusions resolved entirely with a single thoracentesis and adalimumab discontinuation support this being a drug-related complication. Previously published case reports link TNF-alpha inhibitors to pleuropericarditis though this presentation was isolated to pleural involvement.
- |||||||||| Olumiant (baricitinib) / Incyte, Eli Lilly
Trial completion date, Trial primary completion date: CRI-RA: Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis (clinicaltrials.gov) - Feb 15, 2024
P3, N=178, Recruiting,
These results will positively impact the determination of appropriate patient treatment and inform the selection of clinical trial outcome metrics. Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Jul 2025 --> Dec 2025
- |||||||||| Bimzelx (bimekizumab) / UCB
Bimekizumab Efficacy and Safety in Biologic Dmard-Na () - Feb 8, 2024 - Abstract #CRAAHPA2024CRA_AHPA_240;
P3
Patients were randomised 3:2:1 tosubcutaneous BKZ 160 mg every 4 weeks (Q4W):PBO:reference arm (adalimumab [ADA] 40 mg Q2W). BKZ treatment demonstrated consistent sustained clinical efficacy across disease manifestations to Week 52 in bDMARD-na
|
